Physician profile
Heather Willison
NPI 1376030304
$8,539.38
in general payments reported to CMS, 2019-2025
27 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,103 · 2022: $1,759 · 2023: $1,779 · 2024: $2,291 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,542.66 |
| Education | $134.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,113.41 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,388.83 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $828.24 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Genzyme Corporation | $824.95 | 2021-2025 | |
| Csl Behring | $570.71 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Regeneron Healthcare Solutions, INC. | $506.39 | 2023-2025 | Dupixent |
| Amgen INC. | $392.73 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $389.68 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $231.36 | 2023-2025 | Xolair |
| Kaleo, INC. | $217.14 | 2022-2024 | Auvi-Q |
| Pfizer INC. | $154.29 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.60 | 2021-2023 | Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $116.02 | 2023-2025 | |
| Leo Pharma INC. | $104.13 | 2022 | |
| Aimmune Therapeutics, INC. | $88.96 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Pharming Healthcare, INC. | $81.67 | 2024-2025 | Ruconest |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.35 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $58.18 | 2025 | Neffy |
| Greer Laboratories, INC. | $54.70 | 2024-2025 | Oralair, Palforzia |
| Blueprint Medicines Corporation | $24.45 | 2023 | Ayvakit |
| Grifols USA, LLC | $23.11 | 2022 | |
| Alk-Abello, INC | $17.45 | 2021 | |
| Abbvie INC. | $16.00 | 2021 | |
| Lundbeck LLC | $15.47 | 2024 | Vyepti |
| Lilly USA, LLC | $15.33 | 2024 | Ebglyss |
| Merck Sharp & Dohme LLC | $13.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Willison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.